http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112469426-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_26da3723d11a0786897640eceb4d464f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-741 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N63-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-741 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N63-50 |
| filingDate | 2019-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36ec45205f419dffb601a7721fe99dab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd04b25f49873a094ea52d8851882a98 |
| publicationDate | 2021-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112469426-A |
| titleOfInvention | Phage compositions and kits and related methods |
| abstract | A composition for affecting the gut microbiome of a mammalian subject may comprise a pharmaceutically acceptable carrier and greater than or equal to 1 x 10 4 PFU/mL or PFU/mg of bacteriophage, the bacteriophage having a tropism, the tropism Including obesity-causing and/or inflammatory bacteria associated with the gut microbiome of mammals. Processes for preparing the disclosed compositions can include isolating the phage from an environmental source, characterizing the phage, and combining the phage with a pharmaceutically acceptable carrier at greater than or equal to 1 x 10 4 PFU/mL or PFU/mg amount to be combined. The methods can include administering the disclosed compositions to a mammalian subject with or without co-administration of the disclosed probiotics. Administration of the disclosed compositions can reduce the concentration of obesogenic bacteria and/or inflammatory bacteria in the gut microbiome of a mammalian subject, promote or induce weight loss, reduce inflammation, support metabolic health, and/or support mammalian nutrition. Healthy balance/diversity within the subject's gut microbiome. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114292822-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114292822-B |
| priorityDate | 2018-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 381.